Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yu. I. Manusha"'
Publikováno v:
Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії. 19:52-56
The actual problem of modern medicine is the identification of common pathogenetic mechanisms of IHD and NAFLD in order to develop a complex, personalized approach in treatment and prevention of comorbid pathology. Aim of the study: to determine the
Publikováno v:
The Medical and Ecological Problems. 23:3-6
Nowadays, coronary heart disease and non-alchoholic fatty liver disease are significant problems in Ukraine and world. Functional liver disorders potentiate the development and progression of CHD. The initiation process of atherosclerosis is a chroni
Publikováno v:
Biological Markers in Fundamental and Clinical Medicine (collection of abstracts). 3:44-46
DYNAMICS OF MARKERS OF INFLAMMATORY ENDOTHELIUM ACTIVATION IN PATIENTS WITH ISCHEMIC HEART DISEASE IN COMBINATION WITH NON-ALCOHOL FATTY LIVER DISEASE AFTER INFLUENCE BETARGIN AND QUERTSETIN
Publikováno v:
Вісник проблем біології і медицини, Iss 3, Pp 118-121 (2020)
The aim of the study was to examine the correlations between markers of chronic systemic inflammation (CHD), inflammatory endothelial activation, blood lipid spectrum, antioxidant system, liver and heart function in patients with stable coronary hear
Publikováno v:
Biological Markers in Fundamental and Clinical Medicine (collection of abstracts). 3:27-28
THE EFFECT OF BETARGIN ON THE INDICATORS OF CHRONIC SYSTEMIC IN- FLAMMATION, ENDOTHELIAL DYSFUNCTION AND ANTIOXIDANT DEFENSE IN PATIENTS WITH CORONARY HEART DISEASE CONCURRENT WITH NON-ALCO- HOLIC FATTY LIVER DISEASE
Publikováno v:
Biological Markers in Fundamental and Clinical Medicine (collection of abstracts). 2:41-42
DIAGNOSTIC MARKERS OF SYSTEMIC INFLAMMATION IN CORONARY HEART DISEASE IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Publikováno v:
Bulletin of Problems Biology and Medicine. 3:118
Publikováno v:
Вісник проблем біології і медицини, Vol 1, Iss 4, Pp 102-106 (2018)
The aim of the research: to study the influence of betargin on the clinical course of stable coronary heart disease (CHD) and non-alcoholic fatty liver disease (NAFLD), indicators of CSI (TNF?, IL-6 and IL-10), endothelial dysfunction, on the conditi